1. I would be grateful if you could send the Trust’s most recent planning document(s) for the diagnosis and treatment of Alzheimer’s Disease including implementation of lumbar punctures (CSF) and Blood-based Biomarker testing. Please include planning documents that cover the entire Trust and specific department plans, such as neurology, psychiatry, care of the elderly, pathology or memory clinic teams.
2. How many patients were diagnosed with Alzheimer’s Disease (ICD-10 codes = G30, G30.1, G30.8, G30.9, F00, F00.1, F00.2 or F00.9) in your Trust in the last 12-month period for which data are available?
|
|
Number of patients
|
|
Total Alzheimer’ Disease
|
|
3. How many patients were diagnosed with Mild Cognitive Impairment and / or Mild Dementia due to Alzheimer’s Disease (ICD-10 codes = G31.84, G30.1, or MMSE scores = 21 to 24) in your Trust in the last 12-month period for which data are available?
|
|
Number of patients
|
|
Mild cognitive impairment (ICD-10 = G31.84)
|
|
|
Early onset Alzheimer’s Disease (ICD-10 = G30.1)
|
|
|
Mild cognitive impairment (Mini-mental State Examination MMSE = 21 to 24)
|
|
|
Mild cognitive impairment (other sources of definition)
|
|
4. Where, if at all, does the Trust carry out lumbar punctures (cerebrospinal fluid) for diagnosing patients with Alzheimer’s Disease?
|
|
Yes / No
|
|
Lumbar punctures carried out within the Trust itself
|
|
|
Lumbar punctures referred elsewhere and carried out external to the Trust
|
|
|
Trust does not carry out lumbar punctures to diagnose Alzheimer’s Disease
|
|
5. Please provide a list of the full names of other Trusts or other organisations to which the Trust refers patients for lumbar punctures in the diagnosis of Alzheimer’s Disease.
|
Full name of organisation(s)
|
|
|
|
|
|
|
|
|
6. What is the average waiting time for a patient to get an appointment for a lumbar puncture to test for a diagnosis of Alzheimer’s Disease?
|
|
Number
|
|
Average waiting time (weeks)
|
|
7. How many lumbar punctures to test for Alzheimer’s Disease took place in the last 3-month period for which data are available?
|
|
Number of procedures
|
|
Number of lumbar punctures
|
|
8. How many Blood-based Biomarker (BBBM) tests from Cerebrospinal fluid (CSF) to test for Alzheimer’s Disease were conducted in the last 3-month period for which data are available?
|
|
Number of tests
|
|
Number of Blood-based Biomarker tests (CSF)
|
|
9. Where, if at all, does the Trust carry out Blood-based Biomarker (BBBM) tests from Cerebrospinal fluid (CSF) for diagnosing patients with Alzheimer’s Disease?
|
|
Yes / No
|
|
Pathology laboratory within the Trust
|
|
|
Pathology laboratory external to the Trust
|
|
|
Trust does not test for BBBMs to diagnose Alzheimer’s Disease
|
|
10. Please provide a list of the full names of other Trusts or other organisations, to which the Trust refers Blood-based Biomarker tests from cerebrospinal fluid (CSF) for pathology in the diagnosis of Alzheimer’s Disease.
|
Full name of Trust or organisation(s)
|
|
|
|
|
|
|
11. What is the average waiting time for pathology results to come back from Blood-based Biomarker tests?
|
|
Days
|
|
Average waiting time (days)
|
|
12. To what extent are there plans for service improvement of diagnosing Alzheimer’s Disease?
|
|
Yes / No
|
|
Implementation of plans has started
|
|
|
A plan exists and implementation has not started
|
|
|
A plan is being developed
|
|
|
There is no plan
|
|
|
Other – please state
|
|
13. Are the plans for service improvement of diagnosing Alzheimer’s Disease related to:
|
|
Yes / No
|
|
Cognitive assessment services
|
|
|
Biomarker services
|
|
|
None / neither
|
|
14. Which of the following services does the Trust have in place in preparation for increased service delivery for Alzheimer’s Disease?
|
|
Related to administration of lumbar punctures
Yes / No
|
Related to Blood-based Biomarker testing
Yes / No
|
|
Budget
|
|
|
|
People
|
|
|
|
Training
|
|
|
|
Clinic space / capacity
|
|
|
|
Governance arrangements
|
|
|
